Related Experiment Video
Updated: Jun 13, 2026
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
[SOCS1 knockdown sensitize anti-tumor activity of IFN-alpha2a-NGR]
Qi-chao Huang1, Xiao-ying Lei, Yan Liu
1State Key Laboratory of Tumor Biology; Department of Pharmacogenomics, the Fourth Military Medical University, Xi'an 710032, China.
Aim:
Search for key molecules to influence the tumor-targeted IFN-alpha2a-NGR anti-tumor sensitivity through signaling pathway study. Try to enhance the antitumor efficacy of IFN-alpha2a-NGR.
Methods:
MTT method was used to determine the growth inhibitory effects of IFN-alpha2a-NGR on A549 and MKN-45 cells. Flow cytometry and Western blot were employed to detect the expression of STAT1, p-STAT1, p53, OAS and SOCS1; SOCS1 gene knock down was carried out by synthesized siRNA.
Results:
When stimulated with IFN-alpha2a-NGR, the increased expression of STAT1, p-STAT1, p53, OAS and SOCS1 were observed in A549 cells, but only SOCS1 was notably increased in MKN-45 cells. The proliferation inhibition ability of MKN-45 to IFN-alpha2a-NGR was promoted by SOCS1 knocking down. (the inhibition rate was enhanced from 14.69%+/-1.05% to 36.97%+/-2.05%).
Conclusion:
This study has further demonstrated that there were no differences on antitumor effects between IFN-alpha2a-NGR and IFN-alpha2a on cell or molecular level. Besides interferon-alpha receptor (IFNAR) which has been demonstrated before, p-STAT1, p53 and SOCS1 were important determinants of tumor resistance to IFNs therapy. The antitumor efficacy of IFN-alpha2a-NGR can be enhanced by RNA interference. These results might be helpful for the further development of IFN-alpha2a-NGR.
Insights
This study investigated how tumor-targeted interferon-alpha2a-NGR affects anti-tumor sensitivity. Knocking down SOCS1 enhanced the efficacy of interferon-alpha2a-NGR, suggesting a new therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- Interferon-alpha (IFN-alpha) is a crucial cytokine in cancer therapy.
- IFN-alpha2a-NGR is a tumor-targeted variant designed to improve efficacy.
- Understanding resistance mechanisms is key to enhancing IFN-alpha therapy.
Purpose of the Study:
- To identify key molecules influencing tumor sensitivity to IFN-alpha2a-NGR.
- To explore signaling pathways involved in IFN-alpha2a-NGR anti-tumor activity.
- To enhance the anti-tumor efficacy of IFN-alpha2a-NGR.
Main Methods:
- Cell viability was assessed using the MTT assay.
- Expression of STAT1, p-STAT1, p53, OAS, and SOCS1 was analyzed by flow cytometry and Western blot.
- Small interfering RNA (siRNA) was used to knock down SOCS1 gene expression.
Main Results:
- IFN-alpha2a-NGR treatment increased STAT1, p-STAT1, p53, OAS, and SOCS1 in A549 cells, and SOCS1 in MKN-45 cells.
- SOCS1 knockdown significantly enhanced the anti-proliferative effect of IFN-alpha2a-NGR on MKN-45 cells (from 14.69% to 36.97%).
- No significant difference in anti-tumor effects was observed between IFN-alpha2a-NGR and IFN-alpha2a.
Conclusions:
- p-STAT1, p53, and SOCS1 are critical determinants of tumor resistance to Interferon therapy.
- RNA interference targeting SOCS1 can enhance the anti-tumor efficacy of IFN-alpha2a-NGR.
- These findings support the further development of IFN-alpha2a-NGR as a cancer therapeutic.
